PRRT2 and diabetes mellitus: However, a great deal has changed over the last decade and a half; given the ever-advancing state of the literature and increasing evidence speaking to PKC as a major player in diabetes pathology, the time has never been more ripe to revisit the therapeutic potential of RBX (and other PKC inhibitors) in diabetic micro and macro vascular disease.